Here we show that in in vitro models of B-cell lymphoproliferative disorders, i.e., LCL, and B-cell malignancies, i.e., BL, TERT inhibition impairs the transcription of a subset of NF-κB target genes, i.e., MYC, IκBα, BCL2, and Survivin. This evidence concerns the gene MYC and Burkitt lymphoma.